

Building the future of biological AI reasoning


↳ Creating the **superintelligent AI company**
to **autopilot the future of biology research**
& **drug development**





Understanding complex biology is beyond the limits of human intelligence.

To advance drug discovery, development, and diagnostics, we must embrace a new paradigm that uncovers novel insights.





Owkin: The Agentic AI Powerhouse for Biology

Team



325

with top data scientists,
biostatisticians, biologists, MDs

Data



104

global academic institutions to
access thousands of datasets

Science




71

publications in leading
journals like Nature



Owkin is building Biological Artificial SuperIntelligence (BASI) to deliver real world impact



An AI Agent for Biology, powered by multimodal patient data to drive better biopharma decisions



BUILDING BASI

Autopilot superintelligence agent to replace Biology R&D

- Unlocking biology beyond human capacity
- 24/7 insight generation



CONNECTING RESEARCH TO CARE

LAB & PATIENT VALIDATION HUB "reality check"

- Live validation in the lab-in-the-loop
- Validating Tech Hub discoveries in patients
- Factory of SPVs with in-licensed assets
- Portfolio of patient identification tests



Our edge is our data moat: the world's largest AI-ready patient data network powering superior reasoning and agentic capabilities

The Largest Unique Patient Dataset Worldwide

Depth of data

Patient data network

Lab data (incl. Organoids, clinical trials)

Co-pilot feedback loop



Continuous enrichment

Multimodal data

Heterogeneous longitudinal patient data

Cohort specific datasets (latest So)

KOL curated and enriched data

Access to samples, new modality generation

Curated, enriched, QA'd & AI-ready

Competitors

Static time points

One modality only

Cell lines mostly

Historical data only

No KOL curation

No sample access

Unstructured

Breadth of data

1.2M

Patients data at all levels (single cell, longitudinal, multiscale, multimodal (images, pathology, spatial, proteins, RNA, DNA, organs, clinical))

10M

meaningful Q&A extracted from multimodal data

840

hospitals, **104 tier 1 leading academic institutions** & path labs

50

% of the 20 top academic hospitals worldwide

184


world-leading KOLs



Patient data derived organoid models

Agentic data from Owkin K

We map and build high value cohorts



Dynamic data network enriched everyday

Therapy areas: Onco, I&I, Cardiometabolic, Neuro





Synergizing Pharma, Tech, and Academia to Accelerate Agentic AI Innovation

PHARMA

Population & Indication Discovery



Patient Identification

sanofi

SERVIER

Bristol Myers Squibb

AMGEN

MSD


Roche

AstraZeneca

ACADEMIA

840 hospitals, **104 tier 1 leading academic institutions** & path labs

50 % of the 20 top academic hospitals worldwide




TECH

aws


nvidia





K Pro is Owkin's agentic AI tool for smarter

Building the agentic infrastructure for biology to achieve BASI by 2030



Owkin's founder-led leadership team has delivered key AI & scientific breakthroughs




Thomas CLOZEL
(M.D.)
Founder and CEO

- Assistant Professor in clinical oncology
- Former Co-PI at Weill Cornell



Pascal Weinberger
Deputy CEO



Frontier AI for biology



Caroline Hoffmann
Chief Medical Officer



Eric Durand
Chief Research and Technology Officer



Andrew Pierce
SVP Discovery & Development



Healthcare & Business Innovation



Andrea Tassistro
Chief Transformation Officer



Rodrigo Barnes
Chief Technology Officer



Graeme Bell
Chief Financial Officer



Jean-Frederic Petit-Nivard
Chief Business Development Officer



Management & Scaling



Marie-Alice Tantardini
Chief People Officer



Anna Huyghues-Despointes
Chief Corp Dev & Ops Strategy Officer



Antonia Trower
Chief Marketing Officer



Sonia Grouchko
Chief of Staff



Anne-Charlotte Paut
Chief Legal Officer



They already trust Owkin: existing investors are a combination of top tier VCs & Pharma



F/PRIME



sanofi



8[∞] EIGHT ROADS™

NJFCAPITAL
Venture capital arm of NJF Holdings

bpifrance





TOWARDS BIOLOGY ASI



www.owkin.com



thomas.clozel@owkin.com



[@OWKINscience](https://twitter.com/OWKINscience)



[@owkin](#) | [@TClozel](#)



New York, Boston, London, Paris, Nantes, Geneva